tickrz reports
  
tickrz rank
D
Alexion Pharmaceuticals Inc (ALXN)
Healthcare | Biotechnology
CEO: David Richard Brennan
Employees: 2924
alexion.com
FACTOR RANKINGSFACTOR SCREENER 
Pure Value Rank425Dividend RankNO DIVIDEND
Moat Rank300Financial Strength Rank147
Growth Rank16Momentum Rank462
DIVIDEND ANALYSIS
Dividend Yield0%
Payout RatioN/A
3 yr Dividend GrowthN/A
VALUATION RATIOS
P/E Ratio53.94x
P/B Ratio2.91x
P/S Ratio7.91x
EV/EBITDA Ratio24.89x
FINANCIAL STRENGTH
Piotroski F-Score6
Debt-to-Equity37%
Interest Coverage7.32x
MOAT
ROE5.64%
ROIC5.13%
Net Margin13.25%
GROWTH
5 yr EPS Growth14.1%
5 yr SPS Growth30.68%
5 yr BPS Growth44.71%
Alexion Pharmaceuticals Inc 's strong growth translates to a Growth Rank in the top 25% of all stocks
 tickrz summary
Alexion Pharmaceuticals Inc receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
 value
 pure value ranking Warren Buffett ranking
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Alexion Pharmaceuticals Inc's valuation score is comprised of a P/E ratio of 53.9x, a P/B ratio of 2.9x, a P/S ratio of 7.9x, and an EV/EBITDA ratio of 24.9x. Alexion Pharmaceuticals Inc ranks 425 out of the S&P 500 constituents on valuation--a relatively weak score.Alexion Pharmaceuticals Inc ranks 449 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Alexion Pharmaceuticals Inc is probably not for you.

 quality
 moat financial strength
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is average. Our analysis of its moat reveals neither a durable moat or enduring competitive advantages.Alexion Pharmaceuticals Inc has a Piotroski F Score of 6 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 7.32x, a debt/equity ratio of 37% and a Moat Rank of 300 translate to a strong Financial Strength score.


 momentum
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors.The company has seen its stock fall by -13.34% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 462. Based on its 12 month stock performance, Alexion Pharmaceuticals Inc will not appeal to momentum investors.

 yield
 value + yield
Alexion Pharmaceuticals Inc currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

 growth
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 14.1% 5 year annualized EPS growth, 30.7% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 44.7% speak to its impressive growth ranking.

Alexion Pharmaceuticals Inc (ALXN)
Healthcare | Biotechnology
CEO: David Richard Brennan
Employees: 2924
alexion.com


tickrz rank
D

VALUATION RATIOS
P/E Ratio53.94x
P/B Ratio2.91x
P/S Ratio7.91x
EV/EBITDA Ratio24.89x
DIVIDEND ANALYSIS
Dividend Yield0%
Payout RatioN/A
3 yr Dividend GrowthN/A
FINANCIAL STRENGTH
Piotroski F-Score6
Debt-to-Equity37%
Interest Coverage7.32x
MOAT
ROE5.64%
ROIC5.13%
Net Margin13.25%
GROWTH
5 yr EPS Growth14.1%
5 yr SPS Growth30.68%
5 yr BPS Growth44.71%

TICKRZ RANK
Alexion Pharmaceuticals Inc receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Alexion Pharmaceuticals Inc's valuation score is comprised of a P/E ratio of 53.9x, a P/B ratio of 2.9x, a P/S ratio of 7.9x, and an EV/EBITDA ratio of 24.9x. Alexion Pharmaceuticals Inc ranks 425 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Alexion Pharmaceuticals Inc ranks 449 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Alexion Pharmaceuticals Inc is probably not for you.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is average. Our analysis of its moat reveals neither a durable moat or enduring competitive advantages.

FINANCIAL STRENGTH
Alexion Pharmaceuticals Inc has a Piotroski F Score of 6 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 7.32x, a debt/equity ratio of 37% and a Moat Rank of 300 translate to a strong Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors.The company has seen its stock fall by -13.34% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 462. Based on its 12 month stock performance, Alexion Pharmaceuticals Inc will not appeal to momentum investors.

VALUE + YIELD
Alexion Pharmaceuticals Inc currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 14.1% 5 year annualized EPS growth, 30.7% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 44.7% speak to its impressive growth ranking.